ArticleCureus2025
A Rare Cause of Female Virilization: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sertoli-Leydig cell tumors (SLCTs) are uncommon ovarian sex cord stromal neoplasms that typically affect young women and may cause a rise in androgen production. We report a case of a 21-year-old woman who sought medical care because of a two-year amenorrhea, progressive virilization, and a large abdominopelvic mass. Imaging revealed a solid multiloculated adnexal lesion measuring 200 x 80 x 150 mm, associated with a marked hyperandrogenism (total testosterone 584 ng/dL). She underwent surgery for a left adnexectomy, in which no extraovarian involvement was noticed. Histopathology disclosed a moderately differentiated SLCT with mixed Sertoli and Leydig elements, high mitotic activity, and positivity for WT1, CAM5.2, inhibin A, vimentin, and calretinin. Peritoneal cytology was negative, which classified the disease stage as IA. Tumor sequencing identified two somatic DICER1 variants, although not present in peripheral blood, thus excluding a DICER1 syndrome. The patient recovered uneventfully, and at six months after surgery, androgen levels and clinical virilization signs had resolved. Given their usual early presentation, SLCTs are primarily managed surgically with conservative unilateral resection. Prognosis correlates with differentiation and stage. Periodically, clinical and biochemical surveillance is advised, and molecular testing can guide genetic counseling and further management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.